摘要
目的研究利拉鲁肽联合盐酸二甲双胍在2型糖尿病合并非酒精性脂肪性肝病患者中的应用效果。方法本次研究对象选取2019年3月至2020年12月在商丘市中心医院内分泌科治疗的2型糖尿病合并非酒精性脂肪性肝病患者86例,随机分为对照组和治疗组,每组43例。两组患者均在入院后进行常规健康教育、饮食干预及制定相关运动方案。对照组患者在此基础上使用盐酸二甲双胍片,治疗组患者在对照组基础上加用利拉鲁肽注射液,两组患者均持续治疗3个月。比较两组患者治疗前后血糖、血脂、肝功能浓度及治疗期间不良反应发生情况。结果与治疗前比,治疗后两组患者外周血FPG、HbAlc、TC、TG、LDL-C、ALT、AST、γ-GT浓度均显著降低,治疗组下降幅度显著大于对照组;血清FINS、FCP浓度及外周血HDL-C浓度均显著升高,且治疗组高于对照组(均P<0.05);两组患者的总不良反应比较差异无统计学意义(P>0.05)。结论利拉鲁肽联合盐酸二甲双胍能够有效改善2型糖尿病合并非酒精性脂肪性肝病患者血糖、血脂及肝脏功能,且安全性良好。
Objective To study the effect of liraglutide combined with metformin hydrochloride in patients with type 2 di⁃abetes and non-alcoholic fatty liver disease.Methods This study selected 86 patients with type 2 diabetes and non-alcoholic fatty liver disease who were admitted to the Department of Endocrinology of Shangqiu Central Hospital from March 2019 to December 2020,dividing randomly into control group and treatment group,43 cases each.Both groups of patients received routine health education,dietary intervention and related exercise programs after admission.Patients in the control group used metformin hydrochloride tablets on this basis,patients in the treatment group were giv⁃en liraglutide injection on the basis of the control group,both groups of patients continued treatment for 3 months.Compare the levels of blood glucose,blood lipids,liver function and adverse reactions during treatment between the two groups of patients before and after treatment.Results Compared with before treatment,after treatment,the peripheral blood FPG,HbAlc,TC,TG,LDL-C,ALT,AST,γ-GT levels of the two groups of patients were significantly re⁃duced,and the treatment group is lower than the control group;Serum FINS,FCP,concentrations and peripheral blood HDL-C concentration were significantly increased,and the treatment group is higher than the control group(allP<0.05);there was no statistically significant difference in the occurrence of adverse reactions between the two groups of patients(P>0.05).Conclusion Liraglutide combined with metformin hydrochloride can effectively improve blood sugar,blood lipids and liver function in patients with type 2 diabetes and non-alcoholic fatty liver disease,and has good safety.
作者
吴敬
WU Jing(Department of Endocrinology,Shangqiu Central Hospital,Shangqiu,Henan 476000,China)
出处
《医药论坛杂志》
2022年第12期35-39,共5页
Journal of Medical Forum
